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Osteogenesis imperfecta (OI) is a heritable disorder of the bone 
connective tissue characterised by defective bone connective tissue, 
bone fragility and decreased bone mass.[1,2] Frequent bone fractures, 
reduction in bone mass, scoliosis, short stature, progressive long bone 
deformity and hearing loss are some of the features of this disease.[1]
Zeitlin, Fassier and Glorieux quoted the original classification 
as proposed by Sillence.[1] This claassification had four types and 
has been increased to include at least seven types, based on clinical 
and radiographic findings.[3] Type I is the mildest form, presenting 
with occasional fractures before puberty, minimal deformity and 
stature appearing normal. Type II is the most severe and is invariably 
lethal in the antenatal or immediate postnatal period. Uncalcified 
craniums, short limbs and narrow thoracic cavities are some of the 
features. Type III is the most severe type in childhood, presenting with 
frequent fractures leading to severe long bone deformities. It is also 
characterised by short stature. It is very disabling but is not lethal. It 
has traditionally been considered to be autosomal recessive or due to a 
new dominant mutation.[2] Type IV is a mild form of this bone disease 
and presents with variable signs. The blue discolouration of the sclera 
is not apparent after childhood. Type V is moderately deforming, 
presenting with mild to short stature, dislocation of the radial head, 
mineralised interosseous membrane, hyperplastic callus formation, 
white sclera and no dentinogenesis imperfecta. Type VI is moderately to 
severely deforming, presenting with moderately short limbs, scoliosis, 
accumulation of osteoid in bone tissue, fish scale patterns of bone 
lammelation, white sclera and no dentinogenesis imperfecta. Type VII 
is moderately deforming, presenting with a short stature, short humeri 
and femora, coxa vara, white sclera and no dentinogenesis imperfect. 
Types I - IV are due to mutations in collagen genes, but mutations in 
these genes have been excluded in the other types.[1,3]
Beighton estimated the prevalence of OI type III in the black 
population of South Africa (SA) at 1:125 000 to 1:200 000.[4,5] Other 
estimates state that for all types, the prevalence is between 1:10 000 to 
1:20 000.[6]
Until recently, treatment of fractures by means of orthopaedic 
management, which involves immobilisation and rodding, was 
the mainstay of patient care.[1,6] Numerous medical treatments 
to reduce the fracture incidence including vitamin D, fluoride, 
anabolic steroids, magnesium oxide, calcitonin and growth 
hormone have been attempted. None of these have been effective in 
reversing the underlying pathophysiology nor resulted in a clinical 
improvement. [3,6- 8] The aim of pamidronate treatment is to minimise 
fractures and maximise function. Bisphosphonate compounds, 
including pamidronate disodium (Aredia marketed by Novartis, 
Switzerland) and zoledronic acid, have been shown to reduce the 
fracture incidence and morbidity in more severe types of OI.[1] 
Zoledronic acid has been introduced as a treatment for OI after the 
completion of this study.[9,10]
Pamidronate disodium is a bisphosphonate and thus has its effect 
by inhibiting bone reabsorption. It normalises the calcium level in 
hypercalcaemia by inhibiting osteoclast activity. This medication is 
given as a slow intravenous injection and its side-effects, which are 
usually mild and self-limiting, are characterised by a drop in serum 
calcium levels, transient leucopenia, influenza-like symptoms and 
fever reactions.[1,11]
Numerous authors have reported this form of treatment to 
be beneficial, with the effects being characterised by decreased 
fractures, reduction in bone pain and improving the quality of 
life for the patients.[2,6,8,11] However, the majority of research has 
been performed on Canadians, North American Indians and 
Europeans. Very little information regarding patient attitudes or 
subjective assessment could be found when searching PubMed, 
only an assessment of quality of life after administration of 
oral bisphosphonates.[12] No data about pamidronate treatment in 
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black SA patients has been published. The 
efficacy and safety profile in black South 
Africans appears to be similar to published 
data (BD Henderson, presented at the 12th 
SA Society of Human Genetics congress in 
March 2007).
Objective
This study intended to assess subjective data 
regarding OI and pamidronate therapy in 
black patients diagnosed with OI type III 
and treated at Universitas Private Hospital, 
Bloemfontein. This included the side-
effects experienced, impact on the quality 
of their lives and overall attitude towards the 
disorder and the value of treatment.
Methods
A descriptive study using a researcher-
administered questionnaire was undertaken. 
Two researchers interviewed the same 
patient simultaneously. None of the inter-
viewers were involved in administering the 
treatment. This study was performed in 
2009 and 2010 by undergraduate MB ChB 
students at the University of the Free State 
(UFS) and formed part the curriculum.
The protocol was approved by the ethics 
committee of the Faculty of Health Sciences 
at UFS (study No. 15/09). Informed consent 
was obtained from the individual, a parent 
or legal guardian for children, and assent, 
where applicable, from children old enough 
to understand. A pilot study was performed to 
confirm feasibility of the study. These results 
were not included in the study.
The patients approached were receiving 
treat ment or had previously received treat-
ment according to the protocol recom mended 
by Glorieux et al.[1,2,9,13] This entailed a 3-day 
admission every 4 months for intravenous 
administration of pamidronate disodium. 
Thirty patients were approached and 26 
were interviewed during an admission for 
treatment or by telephone. The parents of 
children too young to comprehend or respond 
to the questionnaire were interviewed.
Results
A total of 30 patients were approached 
for inclusion in the study. Of these, 28 
were currently on treatment. Four patients 
did not respond or declined participation. 
All patients were considered to have type 
III OI or Bruck syndrome. The patients 
were resident in the Free State (73.1%) or 
surrounding areas (26.9%). The age range 
was from 1.5 to 24 years with a mean of 
10.5 years. The majority of patients were too 
young to be interviewed and 19/26 (73.1%) 
interviews were conducted with parents. The 
interviews were conducted face-to-face in 
57.7% of cases, while 42.3% were telephonic. 
The female to male ratio was 1.36.
All of the patients were diagnosed with 
the disorder before the age of 10 years old. 
The majority (88.5%) had no knowledge or 
experience of the disorder prior to diagnosis. 
The impact of the disorder on personal 
lives is reflected by parents responding that 
they felt embarrassed and isolated (10/19) by 
the disorder. The children also experienced 
isolation (2/7) and considered themselves 
handicapped and different (5/7) to other 
children. Three of the patients and six of 
the parents had either not considered this or 
considered themselves as normal (3/7 and 
6/19, respectively); others just said they had 
learnt to live with OI.
Fractures and bone pain were the most 
common symptoms experien ced by patients 
prior to initiation of pamidronate treatment. 
These and other symptoms are reflected in 
Fig. 1.
Two of the patients had used other medical 
treatment, namely calcium and vitamin D, 
for management of the disorder and both 
indicated that pamidronate was better.
The siting of an intravenous line was 
not a problem for most of the participants 
with 73.7% of parents interviewed and 
57.1% of patients interviewed tolerating this 
procedure well. For those participants who 
found the insertion of a line a problem, the 
reasons given were pain, discomfort and fear.
All participants felt that the treatment was 
beneficial and the reasons for this perception 
are reflected in Fig. 2. This figure clearly 
indicates that the participants felt that 
pamidronate had not only improved their 
physical wellbeing (fewer fractures, less pain 
and less sweating) but also their emotional 
wellbeing. A large percentage (73.1%) of them 
felt stronger after receiving the treatment.
Side-effects were reported by 61.6% 
of respondents. Of those who experienced 
side-effects, fever and nausea were the most 
common and persisted for a few days (38.5%). 
Side-effects persisted for a few hours in the rest 
of the patients who experienced any (23.1%). 
The side-effects are listed in Table 1. As can 
be noted, 57.9% of parents did not think their 
children experienced side-effects.
One of the two patients who had stopped 
treatment was contacted, and the reasons 
given for stopping treatment were unbearable 
side-effects and not knowing when the next 
admission was scheduled for.
Travelling costs and loss of income were 
not a significant concern for the participants 
with 73.1% indicating an out-of-pocket 
expense of less than R150 and 19.2% 
experiencing loss of income.
All participants felt that a disability 
pension was justified and gave the following 
reasons: Disability makes it difficult to find 
employment with a reasonable salary and it 
is expensive to maintain a dignified lifestyle 
by a person living with a disability.
When asked for an overall opinion of the 
pamidronate treatment, 71.4 % of parents 
interviewed and 68.4% of patients interviewed 
rated the treatment as excellent. All of the 
participants would recommend the treatment 
to other people. This is reflected in Fig. 3.
Discussion
These data indicate that black South 
Africans affected by OI experience similar 
symptoms and responses to the disorder as 
people elsewhere.[1,2,7,10,11] The low number 
of participants reporting prior knowledge 
of the disorder supports the perception of 
an autosomal recessive or new dominant 
mutation as the underlying mechanism of 
disease in OI type III.[6]
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Fig. 1. Symptoms experienced before pamidronate treatment.
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Subjectively, pamidronate treatment is well tolerated and beneficial 
to this population group. The fact that so many rate the treatment as 
excellent must be considered in the light of this being the first medical 
treatment offered to alleviate the symptoms. The children and their 
parents perceive a benefit as demonstrated by the willingness to 
return for treatment every 4 months. The fact that an intravenous line 
was sited, and often replaced, for the duration of each 3-day hospital 
stay was not considered problematic must indicate that benefits 
outweigh this inconvenience. The perception of feeling stronger after 
the infusion would contribute to the positive attitude displayed by the 
participants. This positive attitude is supported by 100% of patients 
being willing to recommend this treatment to other people.
More side-effects were reported by children than parents. This may 
reflect the parents overlooking less striking side-effects such as 
nausea. The number of side-effects reported in this study is higher 
than other studies. The reason for this is unclear but may be due to 
the fact this study looked at collective recall of a number of treatment 
cycles whereas other studies collected data about side-effects during 
a specific treatment cycle.
One-third of participants had not considered themselves as 
different; however, all responded that a disability pension was 
indicated. This difference may reflect a general attitude to pensions in 
SA or reflect high acceptance of disability in the country. This should 
be investigated further.
The fact that many parents were interviewed on behalf of their 
children is a limitation to this study and may introduce a bias. It is 
doubtful that parents would expose their children and themselves to 
the inconvenience and financial strain of a 3-day hospital admission 
unless they perceived a benefit for their child. The low number of 
patients who do not continue receiving treatment would support 
that the parents perceived a benefit for their children but may have 
been a source of bias. For the majority of patients, pamidronate was 
the first medical treatment offered to them and would contribute 
to the high satisfaction experienced. The researchers intended that 
by having researchers not involved with the administration of the 
treatment, bias would be reduced and the participants would state 
their experiences without trying to please the treating physician.
Conclusion
The participants reflected a positive attitude towards pamidronate. 
The prolonged and frequent administration of the medication by an 
intravenous route was not troublesome to the patients. The side-effects 
were bearable and therefore the majority of patients were willing to 
return for every treatment cycle. The patients were satisfied with the 
improvement they experienced. This provides the first subjective 
support for using pamidronate in SA OI patients.
This study supports the use of bisphosphonates in young black 
patients with OI and demonstrates that it is well tolerated despite 
the route of administration. The impact of OI is no different in this 
study population in comparison with data from other populations. 
The parents seem to perceive side-effects differently to the children.
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Table 1. Side-effects experienced
Parents’ response 
(19/26), %
Patients’ response 
(7/26), %
Fever 26.3 42.9
Discomfort 21.1 14.3
Unease 5.3 0.0
Nausea 10.5 42.9
Headache 10.5 28.6
No side-effects 57.9 28.6
Fig. 2. Improvement after pamidronate treatment.
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Fig. 3. Overall rating of pamidronate treatment.
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